Searched for
ASSERTIO HOLDINGS
Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...- Stocks in news: Prime Focus, Groww, GIC RE, Wipro, NykaaIndian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...
- Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...
- Stock Radar: Zydus Lifesciences stock breaks out from inverse head & shoulder pattern to hit fresh 52-week high; time to buy?Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...
- Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
Load More
